CCR6+ immune cells, such as Th17 cells17 and more recently also CCR6+ ILC3,18 demonstrate CNS migration in experimental autoimmune encephalomyelitis (EAE),17, 18 such that the CCR6‐CCL20 axis has been proposed as a future therapeutic target.17 This evidence concerns the gene CCR6 and experimental autoimmune encephalomyelitis.